- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01292772
The Effects of Radiation in Reconstructed Breasts
April 7, 2020 updated by: Abramson Cancer Center of the University of Pennsylvania
The Effects of Radiation Therapy on the Reconstructed Breast: An Evaluation Using MR Imaging
The primary objective of this study is to use LR imaging to evaluate the effects of adjuvant radiation therapy on reconstructed breasts.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Immediate breast reconstruction following mastectomy has become an increasingly popular and accepted treatment option among breast cancer patients.
This change in practice has resulted in a significant number of patients who undergo radiation therapy after breast reconstruction.
Following irradiation, the reconstructed breast often experiences fibrotic contracture, volume loss, altered pigmentation, or some combination thereof, producing an asymmetric and aesthetically compromised result.
The effects of radiation on reconstructed breasts as well as the implications that such changes have for timing of reconstructive surgery, post-operative management and surveillance imaging are topics of growing importance in plastic surgery, radiology and surgical oncology.
Study Type
Observational
Enrollment (Actual)
12
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
The target population will consist of patients with a diagnosis of unilateral breast cancer who elect to undero bilateral mastectomy with immediate free flap reconstruction.
Patients will be treated by members of the Division of Plastic and Reconstructive Surgery and will receive postoperative radiation therapy to the affected breast.
Description
Inclusion Criteria:
- Female patients between 18 and 90 years of age.
- Patients with a diagnosis of unilateral breast cancer who elect to undergo bilateral mastectomy with immediate free flap reconstruction.
- Patients must also have a locally advanced tumor that requires adjuvant radiation therapy following reconstruction.
Exclusion Criteria:
- Women who do not undergo immediate, bilateral breast reconstruction using a free flap.
- Women who do not require unilateral, adjuvant radiation therapy
- Women who are pregnant
- Women who have altered renal function, defined as a personal history of diabetic, hypertensive or autoimmune nephropathy and/or on routine preoperative testing are found to have a serum creatinine greater than or equal to 1.3
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reconstructed Breast Volume
Time Frame: up to 1 year after radiation
|
This will be compared at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Vascular Fibrosis
Time Frame: up to 1 year after radiation
|
This will be compared at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Dermal Thickness
Time Frame: up to 1 year after radiation
|
This will be compared at 2 pionts: before radiation and 1 year after radiation is completed between the 2 breasts
|
up to 1 year after radiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of Fat Necrosis in the Breast
Time Frame: up to 1 year after radiation
|
This will be assessed at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Evidence of Cancer Recurrence
Time Frame: up to 1 year after radiation
|
This will assessed at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Symmetry
Time Frame: up to 1 year after radiation
|
This will be assessed at 2 points; before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Hyperpigmentation
Time Frame: up to 1 year after radiation
|
This will be assessed at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Contracture
Time Frame: up to 1 year after radiation
|
This will be assessed at 2 points:before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Aesthetic Result
Time Frame: up to 1 year after radiation
|
This will be assessed at 2 points: before radiation and 1 year after radiation is completed between the 2 breasts.
|
up to 1 year after radiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2010
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
May 5, 2019
Study Registration Dates
First Submitted
February 1, 2011
First Submitted That Met QC Criteria
February 9, 2011
First Posted (Estimate)
February 10, 2011
Study Record Updates
Last Update Posted (Actual)
April 8, 2020
Last Update Submitted That Met QC Criteria
April 7, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 12110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on contract-enhanced MRI
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
University of CincinnatiActive, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Recruiting
-
Radboud University Medical CenterRecruitingHead and Neck Squamous Cell CarcinomaNetherlands
-
The Hospital for Sick ChildrenTerminatedMetastatic Pulmonary NodulesCanada
-
University of Wisconsin, MadisonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingCirrhosis, Liver | Gastroesophageal VaricesUnited States
-
University of California, BerkeleyEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Nottingham University Hospitals NHS TrustCompletedHead and Neck Squamous Cell CarcinomaUnited Kingdom
-
Seoul National University HospitalCompletedInvasive Breast Cancer | Carcinoma, Ductal, Breast | IMAGEKorea, Republic of
-
Assistance Publique Hopitaux De MarseilleUnknownAnorexia Nervosa | Cardiac AnomalyFrance